BioCentury
ARTICLE | Politics & Policy

FDA revises guidance for HCV therapies

October 17, 2013 12:03 AM UTC

FDA now recommends using sustained virologic response (SVR) at 12 weeks after the end of treatment as the primary endpoint in registration trials of chronic HCV therapies, according to revised draft (...